Needham Maintains Buy on TransMedics Group, Lowers Price Target to $106

Benzinga Newsdesk www.benzinga.com Negative 47.4%

Neg 47.4% Neu 0% Pos 0%

Needham analyst Mike Matson maintains TransMedics Group (NASDAQ:TMDX) with a Buy and lowers the price target from $142 to $106.